



## REGENXBIO to Participate in Upcoming Investor Conferences

October 15, 2025 07:05 AM EDT

ROCKVILLE, Md., Oct. 15, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:

### Chardan's 9th Annual Genetic Medicines Conference

**Panel "Battleground States for Muscular Dystrophies":** Tuesday, October 21 at 2:00 p.m. ET

**Panel "CNS GT – Lessons from Mature Programs & the Field's Next Frontiers":** Tuesday, October 21 at 2:45 p.m. ET

**Location:** New York, NY

### Guggenheim Securities 2<sup>nd</sup> Annual Healthcare Innovation Conference

**Fireside Chat:** Monday, November 10, 2025 at 9:00 a.m. ET

**Location:** Boston, MA

### Stifel 2025 Healthcare Conference

**Fireside Chat:** Tuesday, November 11, 2025 at 1:20 p.m. ET

**Location:** New York, NY

Live webcasts of select events can be accessed in the Investors section of REGENXBIO's website at [www.regenxbio.com](http://www.regenxbio.com). Archived replays of the webcasts will be available for approximately 30 days following the events.

### ABOUT REGENXBIO Inc.

REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit [WWW.REGENXBIO.COM](http://WWW.REGENXBIO.COM).

### Contacts:

Dana Cormack  
Corporate Communications  
[dcormack@regenxbio.com](mailto:dcormack@regenxbio.com)

Investors:  
George E. MacDougall  
Investor Relations  
[IR@regenxbio.com](mailto:IR@regenxbio.com)



View original content to download multimedia: <https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302584430.html>

SOURCE REGENXBIO Inc.